vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是BIOCRYST PHARMACEUTICALS INC的2.0倍（$805.5M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 19.1%，领先41.4%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 28.3%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $291.2M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 25.0%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
BCRX vs NBIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $805.5M |
| 净利润 | $245.8M | $153.7M |
| 毛利率 | 97.7% | 97.8% |
| 营业利润率 | 64.0% | 26.2% |
| 净利率 | 60.5% | 19.1% |
| 营收同比 | 209.1% | 28.3% |
| 净利润同比 | 1017.5% | 49.1% |
| 每股收益（稀释后） | $1.13 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $805.5M | ||
| Q3 25 | $159.4M | $794.9M | ||
| Q2 25 | $163.4M | $687.5M | ||
| Q1 25 | $145.5M | $572.6M | ||
| Q4 24 | $131.5M | $627.7M | ||
| Q3 24 | $117.1M | $622.1M | ||
| Q2 24 | $109.3M | $590.2M | ||
| Q1 24 | $92.8M | $515.3M |
| Q4 25 | $245.8M | $153.7M | ||
| Q3 25 | $12.9M | $209.5M | ||
| Q2 25 | $5.1M | $107.5M | ||
| Q1 25 | $32.0K | $7.9M | ||
| Q4 24 | $-26.8M | $103.1M | ||
| Q3 24 | $-14.0M | $129.8M | ||
| Q2 24 | $-12.7M | $65.0M | ||
| Q1 24 | $-35.4M | $43.4M |
| Q4 25 | 97.7% | 97.8% | ||
| Q3 25 | 98.6% | 98.2% | ||
| Q2 25 | 98.3% | 98.4% | ||
| Q1 25 | 96.9% | 98.4% | ||
| Q4 24 | 95.4% | 98.5% | ||
| Q3 24 | 97.3% | 98.7% | ||
| Q2 24 | 98.4% | 98.4% | ||
| Q1 24 | 98.6% | 98.5% |
| Q4 25 | 64.0% | 26.2% | ||
| Q3 25 | 18.6% | 30.1% | ||
| Q2 25 | 18.2% | 21.2% | ||
| Q1 25 | 14.6% | 4.1% | ||
| Q4 24 | -3.4% | 22.6% | ||
| Q3 24 | 6.6% | 29.5% | ||
| Q2 24 | 8.0% | 24.6% | ||
| Q1 24 | -15.6% | 19.3% |
| Q4 25 | 60.5% | 19.1% | ||
| Q3 25 | 8.1% | 26.4% | ||
| Q2 25 | 3.1% | 15.6% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | -20.4% | 16.4% | ||
| Q3 24 | -12.0% | 20.9% | ||
| Q2 24 | -11.6% | 11.0% | ||
| Q1 24 | -38.1% | 8.4% |
| Q4 25 | $1.13 | $1.49 | ||
| Q3 25 | $0.06 | $2.04 | ||
| Q2 25 | $0.02 | $1.06 | ||
| Q1 25 | $0.00 | $0.08 | ||
| Q4 24 | $-0.13 | $1.00 | ||
| Q3 24 | $-0.07 | $1.24 | ||
| Q2 24 | $-0.06 | $0.63 | ||
| Q1 24 | $-0.17 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $3.3B |
| 总资产 | $514.2M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $713.0M | ||
| Q3 25 | $212.9M | $340.2M | ||
| Q2 25 | $260.0M | $264.0M | ||
| Q1 25 | $295.1M | $194.1M | ||
| Q4 24 | $320.9M | $233.0M | ||
| Q3 24 | $96.8M | $349.1M | ||
| Q2 24 | $78.4M | $139.7M | ||
| Q1 24 | $84.3M | $396.3M |
| Q4 25 | $-119.2M | $3.3B | ||
| Q3 25 | $-387.9M | $3.0B | ||
| Q2 25 | $-421.6M | $2.7B | ||
| Q1 25 | $-451.9M | $2.5B | ||
| Q4 24 | $-475.9M | $2.6B | ||
| Q3 24 | $-468.6M | $2.7B | ||
| Q2 24 | $-475.6M | $2.5B | ||
| Q1 24 | $-476.2M | $2.4B |
| Q4 25 | $514.2M | $4.6B | ||
| Q3 25 | $446.4M | $4.3B | ||
| Q2 25 | $457.2M | $3.9B | ||
| Q1 25 | $480.0M | $3.7B | ||
| Q4 24 | $490.4M | $3.7B | ||
| Q3 24 | $491.3M | $3.5B | ||
| Q2 24 | $472.4M | $3.3B | ||
| Q1 24 | $467.9M | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $386.0M |
| 自由现金流率自由现金流/营收 | 71.6% | 47.9% |
| 资本支出强度资本支出/营收 | 0.2% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.19× | 2.53× |
| 过去12个月自由现金流最近4个季度 | $344.9M | $743.9M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $388.4M | ||
| Q3 25 | $41.6M | $227.5M | ||
| Q2 25 | $41.3M | $102.0M | ||
| Q1 25 | $-27.5M | $64.8M | ||
| Q4 24 | $-5.2M | $242.5M | ||
| Q3 24 | $8.2M | $158.0M | ||
| Q2 24 | $-1.4M | $64.6M | ||
| Q1 24 | $-53.7M | $130.3M |
| Q4 25 | $291.2M | $386.0M | ||
| Q3 25 | $40.3M | $214.3M | ||
| Q2 25 | $41.1M | $89.5M | ||
| Q1 25 | $-27.7M | $54.1M | ||
| Q4 24 | $-5.9M | $235.2M | ||
| Q3 24 | $8.2M | $149.9M | ||
| Q2 24 | $-1.5M | $53.0M | ||
| Q1 24 | $-53.9M | $119.1M |
| Q4 25 | 71.6% | 47.9% | ||
| Q3 25 | 25.3% | 27.0% | ||
| Q2 25 | 25.2% | 13.0% | ||
| Q1 25 | -19.0% | 9.4% | ||
| Q4 24 | -4.5% | 37.5% | ||
| Q3 24 | 7.0% | 24.1% | ||
| Q2 24 | -1.4% | 9.0% | ||
| Q1 24 | -58.1% | 23.1% |
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.1% | 1.9% | ||
| Q4 24 | 0.5% | 1.2% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.1% | 2.0% | ||
| Q1 24 | 0.3% | 2.2% |
| Q4 25 | 1.19× | 2.53× | ||
| Q3 25 | 3.23× | 1.09× | ||
| Q2 25 | 8.12× | 0.95× | ||
| Q1 25 | -859.91× | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
